New insight on inflammation and its management: A Review
DOI:
https://doi.org/10.56511/JIPBS.2017.v4.i04.pp117-126Abstract
Inflammation is the defense mechanism of body in which immune system fights against something that may turn out to be harmful. It is the common link between debilitating conditions such as alzheimers, heart disease, arthritis and cancer. An effective anti-inflammatory strategy for the management of inflammation might be able to inhibit the development of inflammation without interfering in normal homeostasis. This review mainly focuses on the etiology of inflammation and newer molecules to battle the stimulus of inflammation and also accentuate on diverse studies carried out in the past. Thus, the high predominance of inflammation obliges the development of new moiety that could be safe and efficient to confer protection against inflammation is urgently needed
Keywords:
Inflammation, COX, NSAIDs, SEGRA, ResolvinsDownloads
References
Dhingra AK, Chopra B, Dass R and Mittal SK: An update on antiinflammatory compounds: a review. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2015; 14(2): 81-97.
Dellagli M, Lorenzo C, Bade M, Sangiovanni E, Dima L, Bosisio E, Restani P: Critical Reviews in Food Science and Nutrition 2013; 53: 403413.
Xie W, Chipman JG and Robertson DL et al.: Expression of a mitogenresponsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692-2696.
Dhingra AK, Chopra B, Dass R, Mittal SK: A review on COX and their inhibitors: Present and future. IPP 2014; 2(4), 470-485.
Rehman Q, Sack KE: When to try COX-2-specific inhibitors: Safer than standard NSAIDS in some situations. Postgrad Med 1999; 106: 95-106.
Chandrasekharan NV, Dai H and Roos KL et al.: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc Natl Acad Sci USA 2002; 99(21): 13926-13931.
Wang C, Chung M, Lichtenstein A, Balk E, Kupelnick B, Devine D, et al. Effects of omega-3 fatty acids on cardiovascular disease. Evid Rep Technol Assess (Summ) 2004; 94: 1-8.
Miller MJ, Ahmed S, Bobrowski P, Haqqi TM: The chondroprotective actions of a natural product are associated with the activation of IGF-1 production by human chondrocytes despite the presence of IL-1b. BMC Complement Altern Med. 2006; 6: 13.
Weber GF: Why does cancer therapy lack effective anti-metastasis drugs? Cancer Lett 2013; 328: 207-211.
Alizadeh AM, Shiri S and Farsinejad S: Metastasis review: from bench to bedside. Tumour Biol 2014; 35: 8483-8523
Ghosh S, May MJ and Kopp EB: NF-k B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-60.
Flower RJ, Moncada S and Vane JR: Analgesic, antipyretics and antiinflammatory agents: drugs employed in the treatment of gout. In: The Pharmacological Basis of Therapeutics; Goodman LS, Gillman AG, Rall W and Murad F: Ed.; Macmillan: New York, 1992; 674-715.
Talalay P and Talalay P: The importance of using scientific principles in the development of medicinal agents from plants. Acad Med. 2001; 76: 238-47.
Tilley SL, Coffman TM and Koller BH: Mixed messages: Modulation of inflammation in immune responses by prostaglandins and thromboxanes. J Clin Invest 2001; 108: 15-23.
Dellagli M, Lorenzo C, Bade M, Sangiovanni E, Dima L, Bosisio E and Restani P: Critical Reviews in Food Science and Nutrition 2013; 53: 403413.
Schacke H, Schottelius A, Docke WD, Strehlke P, Jaroch S, Schmees N, Rehwinkel H, Hennekes H and Asadullah K: Proc. Natl. Acad. Sci. USA. 2004; 101(1): 227-232.
Keenan PA, Jacobson MW, Soleymani RM, Mayes MD, Stress ME and Yaldoo DT: Neurology 1996; 47(6): 1396-1402.
Gennari C: Br. J. Rheumatol. 1993; 32(2): 11-14.
Sheng Y, Pero RW, Amiri A and Bryngelsson C: Induction of apoptosis and inhibition of proliferation in human tumor cells treated with extracts of Uncaria tomentosa. Anticancer Res. 1998; 18: 3363-8.
Jachak SM: Cyclooxygenase inhibitory natural products: Current status. Curr Med Chem. 2006; 13: 659-78.
Clemett D and Goa KL. Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000; 59: 957-80.
Ehrich EW, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, et al.: Characterization of rofecoxib as a cyclooxygenase2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther. 1999; 65: 336-47.
Feldman M and McMahon AT: Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann. Intern. Med. 2000; 132: 134-143.
Marienfeld R, Neumann M, Chuvpilo S, Escher C, Kneitz B, Avots A, et al: Cyclosporin A interferes with the inducible degradation of NF-k B inhibitors, but not with the processing of p105/NF-k B1 in T cells. Eur J Immunol. 1997; 27: 1601-9.
Lopez-Parra M, Claria J, Planaguma A, Titos E, Masferrer JL, Woerner BM, Koki AT, Jimenez W, Altuna R, Arroyo V, Rivera F and Rodes J: Cyclooxygenase1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. Brit. J. Pharm. 2002; 135: 891-900.
Graham DJ: COX-2 Inhibitors, Other NSAIDs, and Cardiovascular Risk: The Seduction of Common Sense. JAMA 2006; 296: 1653-6.
Hegmann T: A tale of two coxibs. JAAPA 2005; 18: 14-27.
Maroon JC: The Longevity Factor: How Resveratrol and Red Wine Activates Genes for a Longer and Healthier Life. New York: Simon and Schuster; 2009.
Zwillich T: Group calls for 2 arthritis drug bans, public citizen says Celebrex, Bextra share Vioxx’s problems. Available from: http://arthritis.webmd.com/news/20050124/group-calls-2-arthritisdrug-bans ) [Last accessed on 2010 Aug 62]
Farquhar B and Kenney WL: Anti-inflammatory drugs, kidney function, and exercise. Sports Science Exchange 1997; 67(11): Article 4.
Zhang H, Liu C, Ji Z, Liu G, Zhao Q, Ao YG, Wang L, Deng B, Zhen Y, Tian L, Ji L and Liu K: Prednisone adding to usual care treatment for refractory decompensated congestive heart failure. Int. Heart J. 2008; 49(5): 587-595.
Massari F, Mastropasqua F, Iacoviello M, Nuzzolese V, Torres D and Parrinello G: The glucocorticoid in acute decompensated heart failure: Dr Jekyll or Mr Hyde?. Am. J. Emerg. Med. 2012; 30(3): 5-10.
Goppelt-Struebe M, Wolter D and Resch K: Glucocorticoids inhibit prostaglandin synthesis not only at the level of phospholipase A2 but also at the level of cyclo-oxygenase/PGE isomerase. Br. J. Pharmacol. 1989; 98(4): 1287-1295.
Rhen T and Cidlowski JA: Anti-inflammatory action of glucocorticoidsnew mechanisms for old drugs. N. Engl. J. Med. 2005; 353(16): 17111723.
Klein NC, Go CH and Cunha BA: Infections associated with steroid use. Infect. Dis. Clin. North Am. 2001; 15(2): 423-432.
Heinemann A and Schuligoi R: Glucocorticoide – potent und umstritten [Glucocorticoids - potent and controversial]. Osterreichische Apothekerzeitung (in German) 2008; 62(23):
Schacke H, Schottelius A, Docke WD, Strehlke P, Jaroch S, Schmees N, Rehwinkel H, Hennekes H and Asadullah K: Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc. Natl. Acad. Sci. USA. 2004: 101(1): 227-232.
Keenan PA, Jacobson MW, Soleymani RM, Mayes MD, Stress ME and Yaldoo DT: The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology 1996; 47(6): 1396-1402.
Klein NC, Go CH and Cunha BA: Infections associated with steroid use. Infect. Dis. Clin. North Am. 2001; 15(2): 423-432.
Newton R and Holden NS: Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol. Pharmacol. 2007; 72(4): 799-809.
Cavet ME, Harrington KL, Ward KW and Zhang JZ: Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cells. Mol. Vis. 2010; 16: 1791-1800.
Renfro L and Snow JS: Ocular effects of topical and systemic steroids. Dermatol. Clin., 1992; 10(3): 505-512.
Bao F, John SM, Chen Y, Mathison RD and Weaver LC: The tripeptide phenylalanine-(D) glutamate-(D) glycine modulates leukocyte infiltration and oxidative damage in rat injured spinal cord. Neuroscience 2006; 140(3): 1011-1022.
Mathison RD, Malkinson T, Cooper KE and Davison JS: Submandibular glands: novel structures participating in thermoregulatory responses. Can. J. Physiol. Pharmacol. 1997; 75(5): 407-413.
Mathison R, Davison JS and Befus AD: Neuroendocrine regulation of inflammation and tissue repair by submandibular gland factors. Immunol. Today 1994; 15(11): 527-532.
Dery RE, Mathison R, Davison J and Befus AD: Inhibition of allergic inflammation by C-terminal peptides of the prohormone submandibular rat 1 (SMR-1). Int. Arch. Allergy. Immunol. 2001; 124(1-3): 201-204.
Mathison RD, Christie E and Davison JS: The tripeptide feG inhibits leukocyte adhesion. J. Inflamm. 2008; 5(6): 1-10.
Marcus D: Willow bark extract, a useful alternative for the treatment of osteoarthritis: Comment on the editorial by Marcus and Suarez-Almazor (Reply) Arthritis Rheum. 2003; 48: 279-80.
Charles AD: Anti inflammatory Agents: Present and Future. Cell. 2010; 140: 935-950.
Reynolds JF, Noakes TD, Schwellnus MP, Windt A and Bowerbank P: Non-steroidal anti-inflammatory drugs fail to enhance healing of acute hamstring injuries treated with physiotherapy. S Afr Med J. 1995; 85: 517-22.
Barton JL: Patient preferences and satisfaction in the reatment of rheumatoid arthritis with biologic therapy. Patient Prefer. Adher. 2009; 3: 335-344.
Senolt L, Vencovsky J, Pavelka K, Ospelt C and Gay S: Prospective new biological therapies for rheumatoid arthritis. Autoimmun. Rev. 2009; 9: 102-107.
Genant HK, Peterfy CG and Westhovens R: Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann. Rheum. Dis. 2008; 67: 10841089.
Scottish Intercollegiate Guidelines Network. Management of Early Rheumatoid Arthritis. SIGN Publication No. 48. Edinburgh: SIGN, 2000.
Goffe B and Cather JC: Etanercept: An overview. J. Am. Dermatol. 2003; 49(25): S105-111.
Maini RN and Feldman M: How does infliximab work in rheumatoid arthritis? Arthritis Res. 2002; 4(2): S22-8.
Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM and Shaw T: Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 2004; 350: 2572-81.
Koenders MI, Joosten LAB and Van den Berg WB: Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Ann. Rheum. Dis. 2006; 65(3): 29-33.
Pincus T, O’Dell JR and Kremer JM: Combination therapy with disease - modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann. Intern. Med. 1999; 131: 768-74.
Heiligenhaus A, Thurau S, Hennig M, Grajewski RS and Wildner G: Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease. Graefes. Arch. Clin. Exp. Ophthalmol. 2010; 248(11): 1531-51.
Scheinfeld NA: Comprehensive review and evaluation of the side effects of the tumor necrosis factor blockers etanercept, infliximab and adalimumab. J. Dermatolog. Treat. 2004; 15(5): 280-94.
Niemoller TD and Bazan NG: Docosahexaenoic acid neurolipidomics. Prostaglandins Other Lipid Mediat., 2010; 91: 85-89.
Curtis CL, Harwood JL, Dent CM and Caterson B: Biological basis for the benefit of nutraceutical supplementation in arthritis. Drug Discov Today. 2004; 9: 165-72.
Peng Q, Wei Z and Lau BH: Pycnogenol inhibits tumor necrosis factor-a - induced nuclear factor kappa B activation and adhesion molecule expression in human vascular endothelial cells. Cell Mol Life Sci. 2000; 57: 834-41.
Beutler B, Milsark IW and Cerami AC: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229(4716): 869-71.
Yang CS and Wang ZY: Tea and cancer: A review. J Natl Cancer Inst 1993; 85: 1038-49.
Tijburg LB, Mattern T, Foltz JD, Weisgerber UM and Katan MB: Tea flavonoids in cardiovascular diseases: A review. Crit Rev Food Sci Nutr. 1997; 37: 771-85.
Morrison BW, Christensen S, Yuan W, Brown J, Amlani S and Seidenberg B: Analgesic efficacy of the cyclooxygenase-2specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trial. Clin Ther. 1999; 21: 943-53.
Grimm T, Chovanova Z, Muchova J, Sumegova K, Liptákova A, Durackova Z, et al.: Inhibition of NF-kB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol) J Inflamm. 2006; 3: 1.
Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR and Ammon HP: Boswellic acids: Novel, specific, nonredox inhibitors of 5lipoxygenase. J Pharmacol Exp Ther. 1992; 261: 1143-6.
Elmali N, Baysal O, Harma A, Esenkaya I and Mizrak B: Effects of resveratrol in inflammatory arthritis. Inflammation. 2007; 30: 1-6.
Sandoval M, Charbonnet RM, Okuhama NN, Roberts J, Krenova Z, Trentacosti AM, et al.: Cat’s claw inhibits TNF - aproduction and scavenges free radicals: Role in cytoprotection. Free Radic Biol Med. 2000; 29: 71-8.
Caterina MJ and Julius D: The vanilloid receptor: A molecular gateway to the pain pathway. Annu Rev Neurosci. 2001; 24: 487-517.
Vane JR, Bakhle YS and Botting RM: Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 1998; 38: 97-120.
Ohki S, Ogino N, Yamamoto S and Hayaishi O: Prostaglandin hydroperoxidase, an integral part of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem 1979; 254: 829-836.
Smith WL and Song I: The enzymology of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid Mediat 2002; 68(69): 11528.
Kujubu DA, Fletcher BS, Varnum BC, Lim RW and Herschman HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991; 266: 12866-12872.
Xie W, Chipman JG, Robertson DL, Erikson RL and Simmons DL: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA. 1991; 88: 26922696.
O'Banion MK, Sadowski HB, Winn V and Young DA: A serumand glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenaserelated protein. J Biol Chem 1991; 266: 2326123267.
Morita I, Schindler M, Regier MK, Otto JC, Hori T, DeWitt DL, et al.: Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem 1995; 270: 1090210908.
Jones DA, Carlton DP, McIntyre TM, Zimmerman GA and Prescott SM: Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993; 268: 9049-9054.
Tanabe T and Tohnai N: Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 2002; 6869: 95-114.
Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS and Simmons DL: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression". Proc. Natl. Acad. Sci. U.S.A. 2002; 99(21): 13926-31.
Ferrero-Miliani L, Nielsen OH, Andersen PS and Girardin SE: Chronic inflammation: Importance of NOD2 and NALP3 in interleukin-1beta generation. Clin. Exp. Immunol. 2007; 147: 227-235.
Charles A: Dinarello. Anti inflammatory Agents: Present and Future. Cell 2010; 140: 935-950.
Sneader W: The discovery of aspirin: A reappraisal . BMJ (Clinical research ed.) 2000; 321(7276): 1591-1594.
Schror K: Acetylsalicylic acid . Wiley 2009; ISBN 978-3-527-32109-4 .
Warner TD, Warner TD and Mitchell JA: Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?". Proc Natl Acad Sci USA 2002; 99(21): 13371-3.
Burke A, Smyth E and FitzGerald GA: 26: Analgesic Antipyretic and Antiinflammatory Agents". Goodman and Gilman's the pharmacological basis of therapeutics (11 ed.). New York: McGraw-Hill. 2006; pp. 671 –
Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biology 1991; 231: 232-235.
Ferreira SH, Moncada S and Vane JR: Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biology 1971; 231: 237239.
Smith JB and Willis AL: Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biology 1971; 231: 235-237.
Published
How to Cite
Issue
Section
Copyright (c) 2017 Ashwani Kumar Dhingra, Bhawna Chopra, Jagdeep Singh Dua, Deo N. Parsad
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Innovations in Pharmaceutical and Biological Sciences is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at